Verona Pharma plc (I9SA) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.110x

Based on the latest financial reports, Verona Pharma plc (I9SA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€30.56 Million ≈ $35.73 Million USD) by net assets (€278.27 Million ≈ $325.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Verona Pharma plc balance sheet independence to measure how much of total assets are equity-financed.

Verona Pharma plc - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Verona Pharma plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check I9SA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Verona Pharma plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Verona Pharma plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Petro Rio S.A. SA:PRIO3	0.082x
Toro Co NYSE:TTC	0.018x
Hella KGaA Hueck & Co XETRA:HLE	0.175x
L E Lundbergföretagen AB (publ) ST:LUND-B	0.007x
Brenntag SE F:BNR	0.076x
Zabka Group S.A. WAR:ZAB	1.097x
Jiangsu Yanghe Brewery Joint-Stock Co Ltd SHE:002304	0.010x
Sirius XM Holding Inc NASDAQ:SIRI	0.023x

Annual Cash Flow Conversion Efficiency for Verona Pharma plc (2016–2024)

The table below shows the annual cash flow conversion efficiency of Verona Pharma plc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Verona Pharma plc stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€204.56 Million ≈ $239.15 Million	€-122.20 Million ≈ $-142.87 Million	-0.597x	-196.53%
2023-12-31	€249.28 Million ≈ $291.44 Million	€-50.22 Million ≈ $-58.71 Million	-0.201x	+22.44%
2022-12-31	€230.47 Million ≈ $269.44 Million	€-59.86 Million ≈ $-69.98 Million	-0.260x	-15.61%
2021-12-31	€148.00 Million ≈ $173.03 Million	€-33.25 Million ≈ $-38.88 Million	-0.225x	+7.86%
2020-12-31	€184.85 Million ≈ $216.11 Million	€-45.08 Million ≈ $-52.70 Million	-0.244x	+74.74%
2019-12-31	€44.40 Million ≈ $51.91 Million	€-42.87 Million ≈ $-50.12 Million	-0.965x	-325.69%
2018-12-31	€79.86 Million ≈ $93.36 Million	€-18.11 Million ≈ $-21.17 Million	-0.227x	-18.30%
2017-12-31	€107.95 Million ≈ $126.21 Million	€-20.70 Million ≈ $-24.20 Million	-0.192x	-45.96%
2016-12-31	€42.53 Million ≈ $49.72 Million	€-5.59 Million ≈ $-6.53 Million	-0.131x	--

About Verona Pharma plc

F:I9SA Germany Biotechnology

Market Cap

$9.07 Billion

€7.76 Billion EUR

Market Cap Rank

#2369 Global

#492 in Germany

Share Price

€90.20

Change (1 day)

+0.67%

52-Week Range

€87.60 - €91.80

All Time High

€91.80